

**CLAIMS**

1. Composition including myo-inositol hexaphosphate in a form adapted to topical administration  
5 for use in the treatment or prevention of a disease associated with the development of heterogeneous nucleants in a soft tissue.
2. Composition including myo-inositol hexaphosphate according to Claim 1 for use in the  
10 treatment of a disease associated with the development of calcifications in a soft tissue.
3. Composition including myo-inositol hexaphosphate according to any of the preceding claims, in which said soft tissue is a subepithelial tissue.
- 15 4. Composition including myo-inositol hexaphosphate according to Claim 1 and/or 2, in which said soft tissue is a renal tissue.
5. Composition including myo-inositol hexaphosphate according to Claim 1 and/or 2, in which said  
20 soft tissue is a pulmonary tissue.
6. Composition including myo-inositol hexaphosphate according to Claim 1 and/or 2, in which said soft tissue is a cerebral tissue.
7. Composition including myo-inositol  
25 hexaphosphate according to Claim 1 and/or 2, in which said soft tissue is the wall of a blood vessel.
8. Use of a composition according to any of Claims 1 to 5 for the manufacture of a medicament for the treatment of a disease associated with the development of  
30 heterogeneous nucleants in a soft tissue.
9. Use according to Claim 8, in which said disease consists on a subepithelial dystrophic calcification.
10. Use according to Claim 8, in which said disease consists on an arterial calcification.

11. Use according to Claim 8, in which said disease consists on a renal calcification.

12. Use according to Claim 8, in which said disease consists on a cerebral calcification.

5 13. Use according to Claim 8, in which said disease consists on a pulmonary calcification.